Nilutamide: An Antiandrogen for the Treatment of Prostate Cancer

@article{Dole1997NilutamideAA,
  title={Nilutamide: An Antiandrogen for the Treatment of Prostate Cancer},
  author={Ernest J. Dole and Mark T. Holdsworth},
  journal={Annals of Pharmacotherapy},
  year={1997},
  volume={31},
  pages={65 - 75}
}
OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, and adverse effects of nilutamide and to compare this agent with the currently marketed nonsteroidal antiandrogens (i.e., bicalutamide, flutamide) by critically analyzing the published literature. DATA SOURCES: MEDLINE (1980–1995) and CANCERLIT (1991–1995) were searched for English-language publications using the terms nilutamide, bicalutamide, and flutamide alone, and either nilutamide or androgen antagonists in combination… 
The role of antiandrogen monotherapy in the treatment of prostate cancer
TLDR
Current data are inadequate to draw conclusions on the comparative efficacy of flutamide and castration, while nilutamide is not licensed for monotherapy, and bicalutamide has a more favourable side‐effect profile than the other antiandrogens and is more likely to promote compliance.
Nilutamide: possible utility as a second-line hormonal agent.
TLDR
A subset of patients, whose disease progresses with prior antiandrogen therapy, may experience a PSA response to nilutamide, and the role ofnilutamide in such hormone-resistant patients deserves additional prospective study.
Antiandrogen treatments in locally advanced prostate cancer: are they all the same?
  • D. Gillatt
  • Medicine
    Journal of Cancer Research and Clinical Oncology
  • 2006
TLDR
The available evidence indicates that the different antiandrogens should not be regarded as equivalents in clinical practice and so the choice of treatment for patients with prostate cancer should be made on an individual basis.
Tolerability of Antiandrogens in the Treatment of Prostate Cancer
TLDR
Data is presented on the tolerability of the antiandrogens, both steroidal (cyproterone acetate; CPA) and non-steroidal (bicalutamide, flUTamide, nilutamide), across all stages of hormone-responsive prostate cancer.
Antiandrogen monotherapy: indications and results.
TLDR
Bicalutamide 150-mg monotherapy was associated with significant advantages compared with castration, in terms of sexual interest and physical capacity, in patients with either M0 and M1 stage disease, and emerging evidence also supports the use of bicalUTamide 150 mg, both as immediate monotherapy and as adjuvant therapy in early stage (localized or locally advanced) prostate cancer.
Receptor affinity and potency of non-steroidal antiandrogens: translation of preclinical findings into clinical activity
TLDR
This clinical trial of bicalutamide confirms the prediction from preclinical studies that a 50 mg dose of bICALutamide would be appropriate for use in patients with advanced prostate cancer, and demonstrates that this bicalUTamide dose is clinically effective when administered as part of CAB.
Bicalutamide (Casodex®) in the treatment of prostate cancer
  • Y. Fradet
  • Medicine
    Expert review of anticancer therapy
  • 2004
TLDR
Nonsteroidal antiandrogens such as bicalutamide (Casodex®) offer an effective alternative to castration with potential quality-of-life benefits in men with prostate cancer.
Pharmacoeconomics of Available Treatment Options for Metastatic Prostate Cancer
TLDR
Evaluated the pharmacoeconomics of available treatments for metastatic prostate cancer, including hormone-sensitive disease, androgen-independent prostate cancer and locally advanced/progressive disease to address weaknesses in understanding of the economic consequences of therapies for prostate cancer.
Hormone Therapy For Prostate Cancer
TLDR
There is no convincing evidence that neo-adjuvant hormone therapy combined with radical prostatectomy provides long-term efficacy and data from randomised trials and meta-analyses do not provide strong evidence that immediate hormone therapy clearly improves overall survival, although progression-free survival may be prolonged in patients with lymph node positive disease.
HORMONAL THERAPY FOR PROSTATE CANCER: CLINICAL AND EXPERIMENTAL EVIDENCE
TLDR
This chapter systematically review clinical and experimental evidence supporting current strategies of hormonal therapy in PCa, the second leading cause of cancer-related death among men in the United States.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 76 REFERENCES
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.
TLDR
Treatment with le uprolide and flutamide is superior to treatment with leuprolide alone in patients with advanced prostate cancer, and Symptomatic improvement was greatest during the first 12 weeks of the combined androgen blockade.
A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer.
TLDR
A comparison of pharmacologic effects showed that only the incidence of hot flushes was lower in the bicalutamide group, whereas breast tenderness and gynecomastia were more common, which translated into better quality of life during the first several months with regard to sexual relations and sexual functioning.
Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project.
TLDR
The results indicate that nilutamide as a single agent has an acceptable toxicity and a moderate activity, and may maintain sexual interest in a discrete number of cases, and whether monotherapy with nonsteroidal antiandrogens offers a valid option in the palliation of advanced disease remains to be seen in comparative prospective trials.
Pure antiandrogens as monotherapy in prospective studies of prostatic carcinoma.
TLDR
If effectiveness could be proven, especially in comparison to other standard forms of endocrine treatment, the use of a "pure" antiandrogen, especially of a substance with very few side effects, may provide a better quality of life than standard treatment and may therefore be preferable.
Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II multicenter trial.
TLDR
Bicalutamide, 50 mg daily, was well tolerated and has efficacy in metastatic prostate cancer and has led to trials using this antiandrogen at higher doses as monotherapy.
Flutamide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic cancer.
TLDR
Flutamide is a suitable alternative to other systemic treatment in patients with advanced prostatic cancer who wish to preserve sexual potency and in combination with an LHRH agonist flutamide may become a first-line agent for previously untreated patients with cancer of the prostate.
Worldwide activity and safety of bicalutamide: a summary review.
TLDR
Because it is effective and offers better tolerability than flutamide, bicalutamide represents a valid first choice for antiandrogen therapy in combination with castration for the treatment of patients with advanced prostate cancer.
Withdrawal phenomenon with the antiandrogen casodex.
  • P. Nieh
  • Medicine
    The Journal of urology
  • 1995
TLDR
The observations in this report would suggest that the initial and sustained exposure to an antiandrogen is the more important factor in the withdrawal phenomenon rather than the low androgen environment alone that occurs with initial luteinizing hormone-releasing hormone analogue monotherapy, orchiectomy or combination lute inizing hormones-re releasing hormone analogue and anti androgen.
Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial.
TLDR
Nilutamide and Orchiectomy constitute a more effective treatment for metastatic prostatic cancer than orchiectomy alone, and the adverse effects of nilutamide, usually minor, are outweighed by the significant improvements in most disease measures and progression-free survival.
A Controlled Trial of Castration With and Without Nilutamide in Metastatic Prostatic Carcinoma
TLDR
Some benefit is suggested of the combined treatment (orchiectomy + nilutamide) over orchiectomy alone in the treatment of metastatic prostatic carcinoma in patients with disseminated, previously untreated prostate cancer.
...
1
2
3
4
5
...